The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.

开始日期2025-07-07

申办/合作机构

Vera Therapeutics, Inc.

CTRI/2025/05/086952

/ Not yet recruitingN/A

A Multicenter, Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

开始日期2025-06-30

申办/合作机构

Vera Therapeutics, Inc.

NCT07020923

/ Recruiting临床2期

A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients With IgAN

This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept

开始日期2025-05-29

申办/合作机构

Vera Therapeutics, Inc.

100 项与阿塞西普相关的临床结果

登录后查看更多信息

100 项与阿塞西普相关的转化医学

登录后查看更多信息

100 项与阿塞西普相关的专利（医药）

登录后查看更多信息

128

项与阿塞西普相关的文献（医药）

2024-12-19·Iranian Journal of Kidney Diseases

TACI Ig Fusion Protein Inhibits TLR4/MyD88/NF-κB Pathway Alleviates Renal Injury in IgA Nephropathy Rats.

Article

作者: Cheng, Yue ; Sun, Jianhua ; Chen, Peng ; Wang, Caili ; Zhang, Wei ; Li, Zengyan ; Chen, Xinnan

INTRODUCTION:

To evaluate the impact of TACI fusion protein (TACI-Ig) on IgA nephropathy (IgAN) in rats, and to explore its mechanism and relationship with TLR4/MyD88/NF-κB pathway.

METHOD:

Sprague Dawley(SD)rats were divided into six groups: control, model, TACI-Ig low dose (TACI-Ig-L), medium dose (TACI-Ig-M), high dose (TACI-Ig-H), and prednisone acetate (PAT) group. The control group and model group received physiological saline injections, while the TACI-Ig groups were administered doses of 7.18, 14.36, and 28.72 mg/kg of TACI-Ig, respectively. PAT group was pretreated with prednisone acetate. After 8 weeks, kidney weight/body weight ratios, 24-hour urine protein (24 h UP), serum creatinine (SCr), and blood urea nitrogen (BUN) levels were measured. Additionally, concentrations of B cell activating factor (BAFF), APRIL, and Gd-IgA1 were evaluated by using ELISA. Pathological changes in kidney tissues were scored, and TLR4, MyD88, NF-κB expression levels were detected through western blot (WB) and RT-qPCR.

RESULTS:

Renal function assessments showed that the IgAN model group exhibited increased in 24 h UP, SCr, BUN, and elevated serum levels of BAFF, APRIL, Gd-IgA1, alongside higher TLR4/MyD88/NF-κB protein expression. TACI-Ig treatment significantly reduced proteinuria, SCr, BUN, levels of BAFF, APRIL, and Gd-IgA1 in IgAN rats. Pathologically, TACI-Ig ameliorated glomerular mesangial deposition and fibrosis. It also inhibited TLR4/MyD88/NF-κB protein expression, demonstrating anti-inflammatory and immune regulatory effects.

CONCLUSIONS:

TACI-Ig mitigates renal injury in IgAN rats by reducing inflammatory infiltration and IgA deposition and suppressing the pathway of TLR4/MyD88/NF-κB, offering data for developing effective treatments for IgAN.

2024-11-01·International Journal of Clinical Oncology

Current status of BAFF targeting immunotherapy in B-cell neoplasm

Review

作者: Tagami, Nami ; Yuda, Junichiro ; Goto, Yasuyuki

Abstract:

B-cell activating factor belonging to the TNF family (BAFF), also known as B-lymphocyte stimulator (BLyS), plays a crucial role in B-cell development. It has multiple receptors, including BCMA, TACI, and BAFF-R, with diverse roles in different cell types. BAFF induces B-cell proliferation and immunoglobulin secretion, and acts as a survival factor for immature, naive, and activated B cells. Consequently, BAFF-deficient mice often show suppressed humoral responses, while BAFF-overexpressing mice show the higher number of mature B cells and may develop autoimmune-like manifestations and B-cell lymphoproliferative diseases. Elevated BAFF levels are also associated with various hematological malignancies, and its expression correlates with disease progression in some cases. Therefore, BAFF-targeted therapies, such as belimumab, atacicept, and tabalumab, are being explored in clinical trials for conditions like chronic lymphocytic leukemia (CLL) and multiple myeloma. Belimumab, an anti-BAFF monoclonal antibody, is being investigated in combination with rituximab/venetoclax for CLL. Atacicept, a decoy receptor for BAFF and APRIL, showed tolerability in a phase 1b trial for CLL. Tabalumab, another monoclonal antibody targeting BAFF, did not demonstrate significant efficacy in a phase 2 study for relapsed/refractory multiple myeloma. BAFF ligand-based CAR-T cells are designed to target BAFF receptors and show promise in preclinical studies, particularly for B-cell malignancies. The review emphasizes the importance of understanding the roles of BAFF and its receptors in the microenvironment of hematologic malignancies. Targeting BAFF and its receptors presents potential therapeutic avenues, and ongoing clinical trials provide valuable insights.

2024-06-01·Kidney international

A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy

Article

作者: Maes, Bart ; Wei, Xuelian ; Lafayette, Richard ; Barbour, Sean ; Tesař, Vladimír ; Phoon, Richard K S ; Lin, Celia J F ; Kim, Sung Gyun ; Barratt, Jonathan ; Eren, Necmi ; Jha, Vivekanand ; Floege, Jürgen ; Israni, Rubeen ; Singh, Harmeet

Atacicept is a first-in-class, dual anti-B-cell Activation Factor-A Proliferation-Inducing Ligand fusion protein in clinical evaluation for treatment of IgA nephropathy. To compare efficacy and safety of atacicept versus placebo in patients with IgAN, this randomized, double-blind, placebo-controlled phase 2b clinical trial ORIGIN enrolled 116 individuals with biopsy-proven IgA nephropathy. Participants were randomized to atacicept 150, 75, or 25 mg versus placebo once weekly for up to 36 weeks. Primary and key secondary endpoints were changes in urine protein creatinine ratio based on 24-hour urine collection at weeks 24 and 36, respectively, in the combined atacicept 150 mg and 75 mg group versus placebo. The primary endpoint was met at week 24 as the mean urine protein creatinine ratio was reduced from baseline by 31% in the combined atacicept group versus 8% with placebo, resulting in a significant 25% reduction with atacicept versus placebo. At week 36, the key secondary endpoint was met as the mean urine protein creatinine ratio reduced from baseline by 34% in the combined atacicept group versus a 2% increase with placebo, resulting in a significant 35% reduction with atacicept versus placebo. The reduction in proteinuria was accompanied by stabilization in endpoint eGFR with atacicept compared to a decline with placebo at week 36, resulting in significant between-group geometric mean difference of 11%, approximating an absolute difference of 5.7 mL/min/1.73m². Endpoint galactose deficient IgA1 levels significantly decreased from baseline by 60% versus placebo. The safety profile of atacicept was like placebo. Thus, our results provide evidence to support a pivotal, phase 3 study of atacicept in IgA nephropathy.

143

项与阿塞西普相关的新闻（医药）

2025-10-17

·GlobeNewswire-Health Care

Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025

BRISBANE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that data from the ORIGIN Phase 3 clinical trial of atacicept for the treatment of IgA nephropathy (IgAN) will be delivered as a featured late-breaking oral presentation during the opening plenary session of the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas, being held November 6 to 9. In addition, two informational posters will describe the ORIGIN Extend and PIONEER trials of atacicept in IgAN and other autoimmune mediated glomerular diseases. ASN Kidney Week 2025 Presentation Details Title:ORIGIN 3: A Phase 3 Trial of Atacicept in IgANPresenting Author:Richard Lafayette, MD, FACP, Professor of Medicine (Nephrology) and Director of the Glomerular Disease Center at Stanford University Medical CenterAbstract Number:TH-OR083Session Title:Opening Plenary: Featured High-Impact Clinical TrialsSession Date, Time:Thursday, November 6, 2025 from 9:02 AM to 9:14 AM CSTLocation:Hall A, Convention Center Title:ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgANPresenting Author:Richard Lafayette, MD, FACP, Professor of Medicine (Nephrology) and Director of the Glomerular Disease Center at Stanford University Medical CenterPoster Board Number:INFO12-THSession Date, Time:Thursday, November 6, 2025 from 10:00 AM to 12:00 PM CSTLocation:Exhibit Hall, Convention Center Title:PIONEER: A Basket Trial of Atacicept in Autoimmune Mediated Glomerular DiseasePresenting Author:Richard Lafayette, MD, FACP, Professor of Medicine (Nephrology) and Director of the Glomerular Disease Center at Stanford University Medical CenterPoster Board Number:INFO13-THSession Date, Time:Thursday, November 6, 2025 from 10:00 AM to 12:00 PM CSTLocation:Exhibit Hall, Convention Center About Atacicept Atacicept is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated IgAN, lupus nephritis, and other autoimmune kidney diseases. About the Atacicept Clinical ProgramThe ORIGIN Phase 2b clinical trial of atacicept in IgAN met its primary and key secondary endpoints, with statistically significant and clinically meaningful proteinuria reductions and stabilization of eGFR versus placebo through 36 weeks. The safety profile during the randomized period was comparable between atacicept and placebo. Through 96 weeks, atacicept demonstrated further improvements in Gd-IgA1, hematuria, and proteinuria, as well as stabilization of eGFR reflecting a profile consistent with that of the general population without IgAN. The ORIGIN Phase 3 trial met the primary endpoint with a statistically significant and clinically meaningful reduction in proteinuria at week 36, in the prespecified interim analysis. Across the ORIGIN program in IgAN, the safety profile of atacicept appears favorable, and comparable to placebo. Atacicept has received FDA Breakthrough Therapy Designation for the treatment of IgAN, which reflects the FDA’s determination that, based on an assessment of data from the ORIGIN Phase 2b clinical trial, atacicept may demonstrate substantial improvement on a clinically significant endpoint over available therapies for patients with IgAN. Vera Therapeutics believes atacicept is positioned for best-in-class potential, targeting B cells to reduce autoantibodies and having been administered to more than 1,500 patients in clinical trials across different disease areas. The ORIGIN Extend study provides ORIGIN study participants with extended access to atacicept until its potential commercial availability in their region and captures longer-term safety and efficacy data. Atacicept is also being evaluated in expanded IgAN populations, anti-PLA2R positive primary membranous nephropathy, and anti-nephrin positive focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) patients in the PIONEER trial. About Vera TherapeuticsVera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both BAFF and APRIL, which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell–mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868. For more information, please visit www.veratx.com. Forward-looking StatementsStatements contained in this press release regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the advancement, clinical development, regulatory milestones and commercialization of atacicept; the potential for atacicept to be best-in-class; and Vera Therapeutics’ plans, commitments, aspirations and goals under the caption “About Vera Therapeutics”. Words such as “believe,” “plan,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics’ business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics’ filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. For more information, please contact: Investor Contact:Joyce AllaireLifeSci Advisors212-915-2569jallaire@lifesciadvisors.com Media Contact:Debra CharlesworthVera Therapeutics415-854-8051corporatecommunications@veratx.com

临床3期临床结果临床2期引进/卖出突破性疗法

2025-09-29

·CPHI制药在线

国产新药发力IgA肾病赛道，泰它西普、HSK39297双药同步获审评加速

关注并星标CPHI制药在线 9月28日，CDE官网显示，IgA肾病领域传来两则喜讯：荣昌生物的泰它西普注射液拟纳入优先审评，用于治疗具有进展风险的原发性免疫球蛋白A（IgA）肾病成人患者，显著降低蛋白尿水平；海思科的HSK39297片拟纳入突破性治疗品种，用于治疗原发性IgA肾病。关于泰它西普泰它西普（商品名：泰爱）是荣昌生物自主研发的一款 BLyS/APRIL 双靶点融合蛋白创新药，通过同时抑制 BLyS 和 APRIL 两个细胞因子的过度表达，阻止 B 细胞的异常分化和成熟，从而治疗B细胞介导的多种免疫性疾病。目前，泰它西普已在国内获批三项适应症，即系统性红斑狼疮（SLE）、类风湿关节炎（RA）和全身型重症肌无力（gMG）。而且，泰它西普还于2025年9月在国内递交第四项适应症上市申请，用于治疗干燥综合征。 2025年8月，荣昌生物宣布泰它西普治疗原发性IgA肾病的国内3期临床达到研究A阶段的主要研究终点：与安慰剂组相比，泰它西普组患者在治疗39周时24小时尿蛋白肌酐比值（UPCR）降低了55%（P<0.0001）。而且，泰它西普表现出良好的耐受性和安全性。随着适应症的不断扩张，泰它西普销售额逐渐攀升，据悉其2024年销售额飙升至9.7亿元，同比增长88%，单年销量突破150万支。而且，2025年6月泰它西普顺利出海，荣昌生物将其在除大中华区以外的全球范围内的开发和商业化权利独家授权给美国Vor Biopharma公司，据悉交易总金额高达42.3亿美元。关于HSK39297 HSK39297是海思科独立研发的一款高效、高选择性口服补体因子B（CFB）抑制剂，作用于补体旁路途径，兼具控制血管内、外溶血的双重潜力。这一机制精准切中IgA肾病的病理要害——研究证实，补体旁路途径异常激活是疾病进展的关键推手，而CFB作为该途径的核心调控分子，其活性异常会直接导致肾小球炎症损伤与纤维化。通过特异性抑制 CFB，HSK39297 可从源头阻断补体级联反应，减少IgA沉积引发的免疫损伤。目前，HSK39297治疗IgA肾病的2期临床试验已正式启动，其治疗阵发性睡眠性血红蛋白尿症（PNH）临床试验也已推进至3期阶段。值得一提的是，HSK39297治疗PNH的2期临床研究已取得积极结果：经过24周的治疗，所有治疗组均达到预设的主要有效终点，患者的血管内溶血整体得到有效控制，贫血明显改善、输血需求减少。而且，HSK39297安全耐受性良好。目前，全球仅伊普可泮（诺华）一款CFB抑制剂获批治疗IgA肾病，但需每日口服给药两次。HSK39297是国内第二、全球第三款进入临床后期的CFB抑制剂，仅需每日给药一次，有望凭借更好的患者依从性从CFB抑制剂领域脱颖而出。 IgA肾病治疗进展 IgA肾病是全球范围内最常见的原发性肾小球疾病之一，是导致慢性肾病和肾功能衰竭的主要病因。根据弗若斯特沙利文测算，2030年全球IgA肾病患者将达到1016万人。糖皮质激素和免疫抑制剂是IgA肾病传统质量的主要药物，但糖皮质激素长期使用存在诸多不良反应，如感染风险增加、骨质疏松、满月脸等。免疫抑制剂也同样有诸多副作用，如环磷酰胺可能导致骨髓抑制、出血性膀胱炎等。近年来，随着对其发病机制研究的不断深入，IgA肾病的治疗也迎来多款新药，如布地奈德肠溶胶囊（Calliditas/云顶新耀）、伊普可泮(诺华)、阿曲生坦（Chinook/诺华）、司帕生坦（Travere Therapeutics）。其中布地奈德肠溶胶囊是全球首个针对IgA肾病对因治疗的药物，其通过特殊肠溶胶囊设计，在回肠末端靶向释放，抑制肠道黏膜淋巴组织（如派尔集合淋巴结）中致病性IgA（Gd-IgA1）的产生，从源头减少IgA免疫复合物沉积。2021年12月，该药被FDA加速批准用于降低有疾病快速进展风险的成人原发性IgA肾病患者的蛋白尿。阿曲生坦是一种高选择性的内皮素A（ETA）受体拮抗剂，其高选择性使其能够精准地抑制ETA受体介导的有害效应，同时避免了阻断内皮素B（ETB）受体可能带来的水钠潴留等副作用。2025年4月，该药获FDA加速批准用于治疗IgA 肾病，成为首个治疗IgA肾病的强效选择性口服 ETA受体拮抗剂。司帕生坦是全球首个获批上市的具有内皮素A型（ETA）受体（ETA）和血管紧张素II型1受体（AT1R）双重拮抗作用的小分子药物，2023年2月获FDA加速批准，用于降低患有IgA肾病且有疾病快速进展风险的成人（尿蛋白与肌酐比值(UPCR)大于或等于1.5g/g）的蛋白尿。在国内，目前布地奈德肠溶胶囊、伊普可泮和阿曲生坦均已被NMPA批准用于治疗IgA肾病。据悉布地奈德肠溶胶囊2025年8月实现发货超13万瓶，单月销售收入达5.20亿元。此外，全球还有多款在研IgA肾病新药，其中大冢制药的Sibeprenlimab进展较快，2025年3月向FDA递交了治疗IgA肾病的BLA。该药是一款抗增殖诱导配体（APRIL）单抗，通过结合和中和APRIL，减少IgA和致病性半乳糖缺乏型 IgA1 (Gd-IgA1)的数量。通过减少 Gd-IgA1的产生，Sibeprenlimab有助于减缓肾脏损伤和向终末期肾病(ESKD) 进展。已公布的2期临床试验结果显示：与安慰剂治疗相比，IgA肾病患者接受为期12个月的Sibeprenlimab治疗后，蛋白尿状况显著减少，eGFR下降延缓。诺华/Chinook Therapeutic的Zigakibart、Vertex /Alpine的Povetacicept、渤健的Felzartamab、Vera Therapeutics的Atacicept、恒瑞医药的HRS-5965、智康弘义的SC0062等也进展较快，治疗IgA肾病的临床试验已进入3期阶段。不过这些药物作用机制多样，其中Zigakibart是一款抗APRIL人源化单抗。Povetacicept和Atacicept均是Fc 融合蛋白，能够抑制BAFF和APRIL，从而减少B细胞的激活和自身抗体的产生。Felzartamab是一种抗CD38单抗。HRS-5965是一种新型口服CFB抑制剂。SC0062是一款高选择性ETA受体小分子拮抗剂。总结整体来看，近年来IgA肾病治疗取得重大进展，多款新药接连获批上市。而且，国内外还有多款在研IgA肾病新药进入3期临床，且这些药物作用靶点非常多样化。值得期待的是，越来越多的国产新药进军IgA肾病领域，并取得积极临床试验数据。 END 来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

优先审批临床3期突破性疗法临床2期申请上市

2025-08-13

·医药笔记

诺华：BAFF-R抗体干燥综合征、ITP三期临床接连成功

▎Armstrong 2025年8月11日，诺华宣布BAFF-R抗体Ianalumab治疗干燥综合征的量项三期临床NEPTUNUS-1、NEPTUNUS-2均达到主要终点，疾病活动度显著改善。Ianalumab有望成为首款干燥综合征新药。 2025年8月12日，诺华公布Ianalumab用于经激素治疗失败原发免疫性血小板减少症（ITP）的三期临床VAYHIT2顶线数据，关键次要终点治疗6个月时血小板计数显著改善。诺华预计将在2027年与一线治疗VAHIT1的结果一起递交上市申请。 Ianalumab最初由Morphosys（2024年被诺华29亿美元收购）研发，Morphosys为抗体工程的先驱，有多款合作开发的抗体药物管线，包括诺华合作的BAFF-R抗体Ianalumab、Anthos合作的FXI抗体Abelacimab、Ultragenyx合作的硬骨素抗体Setrusumab、礼来合作的ACVR2B抗体Bimagrumab、HiBio及天境生物合作的CD38抗体Delzartamab等。 BAFF-R在成熟B细胞的存活中发挥着关键作用，为BAFF的主要受体之一，TACI则同时为BAFF、APRIL的受体。TACI靶点泰它西普已经成药，Atacicept、Povetacicept则在仅仅追赶。诺华Ianalumab则引领了BAFF-R的临床探索，直到如今在干燥综合征、ITP完成POC。总结除了干燥综合征、ITP，诺华围绕Ianalumab还在探索狼疮性肾炎、系统性红斑狼疮、化脓性汗腺炎、全身性硬皮病等多项自免适应症。诺华在自免领域积累深厚，引领了IL-17A抗体、BTK抑制剂、BAFF-R抗体、CAR-T等多个赛道的进展。 Armstrong技术全梳理系列 GPRC5D靶点全梳理； CD40靶点全梳理； CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向； Claudin 6靶点全梳理； Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇； CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理； Ambrx技术全梳理； Vir Biotech技术全梳理； Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理； Momenta技术全梳理； NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

临床3期免疫疗法细胞疗法抗体药物偶联物并购

100 项与阿塞西普相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09704	阿塞西普	-	DB06399

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
免疫球蛋白a肾病	临床3期	美国	Vera Therapeutics, Inc.	2023-06-29
系统性红斑狼疮	临床3期	美国	Merck KGaA	2008-01-01
系统性红斑狼疮	临床3期	阿根廷	Merck KGaA	2008-01-01
系统性红斑狼疮	临床3期	澳大利亚	Merck KGaA	2008-01-01
系统性红斑狼疮	临床3期	奥地利	Merck KGaA	2008-01-01
系统性红斑狼疮	临床3期	保加利亚	Merck KGaA	2008-01-01
系统性红斑狼疮	临床3期	克罗地亚	Merck KGaA	2008-01-01
系统性红斑狼疮	临床3期	捷克	Merck KGaA	2008-01-01
系统性红斑狼疮	临床3期	法国	Merck KGaA	2008-01-01
系统性红斑狼疮	临床3期	德国	Merck KGaA	2008-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04716231 (ORIGIN, GlobeNewswire) 人工标引	临床2期	免疫球蛋白a肾病	116	Atacicept	窪網齋鑰夢廠廠遞願襯(願鑰膚鹹構鹹憲繭齋襯) = 願餘網廠醖積鹹壓構鏇艱夢築築廠鑰鏇鏇積窪 (艱齋糧獵衊選繭製餘膚 ) 更多	积极	2024-10-26
				Placebo	-
ISN WCN2024	N/A	免疫球蛋白a肾病	-	Atacicept 150 mg	獵觸糧積網鹽範鏇簾壓(憲鹽夢鑰選衊廠夢築構) = 獵膚廠廠積鬱選艱襯築餘選鹹選襯遞齋膚鹹構 (顧襯願壓鬱鹹齋淵製膚 )	-	2024-04-01
				Placebo	獵觸糧積網鹽範鏇簾壓(憲鹽夢鑰選衊廠夢築構) = 廠鬱餘壓夢衊廠製願齋餘選鹹選襯遞齋膚鹹構 (顧襯願壓鬱鹹齋淵製膚 )
NCT04716231 (ORIGIN, Literature) 人工标引	临床2期	免疫球蛋白a肾病	116	atacicept 25 mg	製選願鑰積網鏇齋選窪(獵製淵築醖衊蓋顧鏇範) = similar across the atacicept dose groups and placebo. 醖遞鬱淵範觸廠範夢廠 (鬱範襯願範鹹鹹鏇鹹網 )	积极	2024-03-27
				atacicept 75 mg
NCT04716231 (ORIGIN, GlobeNewswire) 人工标引	临床2期	免疫球蛋白a肾病	-	Atacicept	繭齋獵獵構窪夢窪衊醖(築襯網範遞遞窪觸餘鹹) = met its primary endpoint 積製鑰餘願糧廠夢廠淵 (範觸遞鏇壓鏇繭顧網鬱 ) 达到更多	积极	2024-01-08
				Placebo
NCT04716231 (ORIGIN \| JANUS, GlobeNewswire) 人工标引	临床2期	免疫球蛋白a肾病	-	atacicept (JANUS)	鬱繭醖築範繭構衊遞簾(繭鹹衊構壓簾鑰觸鑰壓) = Through the randomized, placebo-controlled period, infections were balanced between atacicept and placebo in both the Phase 2a JANUS and Phase 2b ORIGIN studies. 鏇齋餘構遞廠觸積齋範 (醖蓋構夢鑰廠糧艱憲製 )	积极	2023-11-04
				placebo (JANUS)
NCT02808429 (Phase II study, CTgov)	临床2期	免疫球蛋白a肾病	16	Placebo (Placebo)	糧鹹夢獵鏇網衊餘艱遞 = 鬱壓糧網鹹膚醖簾鏇襯淵鬱遞觸餘淵獵憲餘範 (膚鏇觸餘齋觸襯繭窪壓, 選鹽餘鏇製鹽齋範淵餘 ~ 窪製鏇遞齋廠廠齋廠蓋) 更多	-	2021-02-25
				Atacicept 25 mg (Atacicept 25 mg)	糧鹹夢獵鏇網衊餘艱遞 = 繭齋積構製醖網遞積醖淵鬱遞觸餘淵獵憲餘範 (膚鏇觸餘齋觸襯繭窪壓, 繭鏇鏇簾繭選衊選艱鬱 ~ 夢製構構鹽艱鏇醖膚齋) 更多
NCT02070978 (ADDRESS II, Pubmed \| Rheumatology (Oxford))	临床2期	系统性红斑狼疮	253	Atacicept 75 mg	襯廠鏇廠艱鬱簾顧齋願(廠艱遞選構遞遞鹽齋夢) = 鏇簾膚鏇窪襯衊夢製鏇構膚鹹簾憲夢夢觸糧糧 (選窪鹽範遞齋鹹艱簾衊 ) 更多	-	2021-02-06
				Atacicept 150 mg	襯廠鏇廠艱鬱簾顧齋願(廠艱遞選構遞遞鹽齋夢) = 簾襯獵獵膚獵築蓋顧簾構膚鹹簾憲夢夢觸糧糧 (選窪鹽範遞齋鹹艱簾衊 ) 更多
NCT02808429 (Phase II study, ERA2020)	临床2期	蛋白尿 \| 免疫球蛋白a肾病 Gd-IgA1	-	Placebo	獵選製壓夢壓壓餘衊範(簾製鹹製憲獵顧窪憲選) = 構窪壓糧顧構積廠顧獵齋鬱積遞鑰顧鬱艱鹹繭 (窪衊積壓廠壓醖夢繭餘 )	积极	2020-06-06
				Atacicept 25mg	獵選製壓夢壓壓餘衊範(簾製鹹製憲獵顧窪憲選) = 構鹽鑰製夢積夢衊齋遞齋鬱積遞鑰顧鬱艱鹹繭 (窪衊積壓廠壓醖夢繭餘 )
NCT01972568 (ADDRESS II, Pubmed \| Rheumatology (Oxford))	临床2期	系统性红斑狼疮	306	Atacicept 150 mg	廠網膚憲蓋鑰鏇築窪網(艱夢製窪餘製構膚願鑰): OR = 3.82 (95% CI, 1.44 ~ 10.15), P-Value = 0.007 更多	-	2020-02-27
				Placebo